Tech Company Financing Transactions
Eloxx Pharma Funding Round
Pontifax Fund, GF Securities and Quark Venture joined a $24 million Series C funding round for Eloxx Pharma. The round was announced on 6/12/2017.
Transaction Overview
Company Name
Announced On
6/12/2017
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series C
Investors
Proceeds Purpose
The funds raised will be used to initiate multiple clinical studies for the company's lead compound, ELX-02. Quark, a Canadian venture capital firm, and China's GF Securities are currently raising a $500 million health sciences fund.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
950 Winter St.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Eloxx Pharmaceuticals is a clinical stage company developing first in class therapeutics for the treatment of genetic disease caused by non-sense mutations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bob Ward
Chief Financial Officer
Gregory Weaver
Chief Operating Officer
Gregory Williams
Founder
Silvia Noiman
VP - Bus. Development
David Snow
Browse more venture capital transactions:
Prev: 6/12/2017: Alzheon venture capital transaction
Next: 6/12/2017: Spektral venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We record every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs